

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 69501

Manuscript Type: ORIGINAL ARTICLE

Retrospective Study

Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival

Yamada K *et al.* Effect of GI-irAEs in ICI-treated patients

Match Overview

1	Crossref 85 words "Rheumatic Diseases and Syndromes Induced by Canc... Immunotherapy", Springer Science and Business Media L	2%
2	Internet 47 words crawled on 06-Jul-2020 www.mdpi.com	1%
3	Internet 46 words crawled on 17-Sep-2020 www.karger.com	1%
4	Internet 33 words crawled on 28-Jun-2021 www.frontiersin.org	1%
5	Crossref 25 words Bi-Cheng Wang, Zhan-Jie Zhang, Chen Fu, Chang Wang. "Efficacy and safety of anti-PD-1/PD-L1 agents vs chem...	1%
6	Internet 24 words crawled on 21-Jul-2021 www.wjgnet.com	1%
7	Internet 22 words crawled on 28-Jun-2020 www.nature.com	<1%
8	Crossref 15 words Hamzah Abu-Sbeih, Faisal S. Ali, Wei Qiao, Yang Lu, Sap na Patel, Adi Diab, Yinghong Wang. "Immune checkpoint i	<1%

ALL

IMAGES

VIDEOS

144,000 Results

Any time ▾

Immune-Related Adverse Events and Immune Checkpoint ...

<https://pubmed.ncbi.nlm.nih.gov/31943525>

Introduction: **Immune-related adverse event** (IRAE) onset may represent a **clinical** biomarker for anti-programmed cell death protein 1 (PD-1) antibody response based on emerging evidence from patients with various advanced malignancies. This phenomenon has not been previously reported in a multidisease cohort of patients with **gastrointestinal (GI)** cancer with Food and Drug Administration ...

Cited by: 5

Author: Satya Das, Kristen K. Ciombor, Sigurd Har...

Publish Year: 2020

Management of Immune-Related Adverse Events in Patients ...

<https://ascopubs.org/doi/full/10.1200/JCO.2017.77.6385>

Feb 14, 2018 · The most common **clinical** presentations of **immune-related GI** toxicities vary from very frequent and/or loose stools to colitis **symptoms** (eg, mucous in the stools, abdominal pain, fever, rectal bleeding). 18 The onset of these **GI symptoms** is most often in the range of 5 to 10 weeks after initiation of **ICPi** but can occur or recur months after discontinuation of immunotherapy. 5,18 While **clinical factors** ...

Cited by: 1782

Author: Julie R. Brahmer, Christina Lacchetti, Bryan...

Publish Year: 2018

PEOPLE ALSO ASK

What are the side effects of immune checkpoint inhibitors? ▾

How to manage immune related adverse events (ICPI)? ▾